Fig. 1.
Effects of formyl peptide receptor 1 (FPR1) pharmacologic modulation on specialized proresolving mediator (SPM) biosynthetic machinery of colorectal carcinoma (CRC) cells. (A) ALOX5, ALOX15A, ALOX15B, GPR32, ChemR23 and BLT1 mRNA fold change in HT29 and HCT116 cells treated with fMLF (10−9 m) or CsH (800 nm) for 3 h. Data are represented as mean ± SD of five independent experiments. *P < 0.05 compared with the control (dotted line) by Student's t test. (B) ALOX5, ALOX15A, ALOX15B, BLT1 and ChemR23 protein expression levels (mean fluorescence intensity), assessed by cytofluorimetric analysis, in HT29 cells treated with fMLF (10−9 m) or CsH (800 nm) for 6 h. A representative experiment of three independent experiments is shown. (C) ALOX5, ALOX15A, ALOX15B, GPR32, ChemR23 and BLT1 protein expression levels (mean fluorescence intensity), assessed by cytofluorimetric analysis, in HCT116 cells treated with fMLF (10−9 m) or CsH (800 nm) for 6 h. Data are represented as mean ± SD of three independent experiments. *P < 0.05 compared with the control (NT) by Student's t test. (D) Proresolving and proinflammatory autacoid (RvD1, LXA4, LXB4, PGE2) release in HCT116 and HT29 cells treated or not with fMLF (10−9 m) or CsH (800 nm) for 12 h. Baseline values of each mediator were in HCT116: RvD1 118 ± 18 pg/106 cells, LXB4 34 ± 5 pg/106 cells, LXA4 485 ± 58 pg/106 cells and PGE2 98 ± 12 pg/106 cells. Baseline values of each mediator were in HT29: RvD1 132 ± 24 pg/106 cells, LXB4 32 ± 4 pg/106 cells, LXA4 462 ± 48 pg/106 cells and PGE2 86 ± 11 pg/106 cells. Data are represented as mean ± SD of changes over baseline levels obtained in five independent experiments. *P < 0.05 compared with the control by Student's t test. [Colour figure can be viewed at wileyonlinelibrary.com]